（文章来源：证券日报） 证券日报网讯 2月25日，吉林敖东在互动平台回答投资者提问时表示，公司管理者积淀的战略定力与中 医药文化底蕴，是公司稳健发展的宝贵财富。公司始终坚持守正与创新并重，在传承优良传统的同时， 持续完善人才梯队建设，优化治理结构，健全人才培养、引进与授权机制，为企业注入活力。公司将坚 守医药主业，不断提升治理水平与创新能力，实现稳健经营与高质量发展，切实回报广大投资者。 ...

（文章来源：证券日报） 证券日报网讯 2月25日，吉林敖东在互动平台回答投资者提问时表示，公司围绕医药主业，积极借鉴行 业优秀经验，推动医药生产、制造的智能化升级与数字化发展，助力中医药现代化进程。公司以开放姿 态积极对接具备先进经营理念、技术优势与产业协同的优质合作方，不断优化经营模式，提升运营效率 与核心竞争力。目前公司正积极推进医药营销改革，通过整合各营销板块、组建营销事业群，优化管理 体系、形成发展合力、统一资源，实现营销突破，助力公司高质量发展。 ...

Investment Rating - The report maintains an "Overweight" rating for the securities and banking sectors [9]. Core Insights - The report highlights the structural relaxation of refinancing policies, which is expected to improve profitability in the banking sector. The central bank's Q4 monetary policy report emphasizes the implementation of personal credit repair measures, supporting micro-entities [1][28]. - The report identifies investment opportunities in the order of securities > insurance > banking, with a focus on the potential for marginal improvements in the brokerage business due to the recent refinancing policy adjustments [12][24]. Summary by Sections Securities Sector - The optimization of refinancing measures announced by the exchanges is expected to lead to marginal improvements in the brokerage business, with leading firms likely to solidify their advantages through professional capabilities. The Chinese brokerage index performed better than the Hang Seng index during the holiday period, increasing by 0.20% [2][13]. - Recommended stocks include leading brokerages such as CITIC Securities, Guotai Junan, and GF Securities, as well as quality regional firms like Guoyuan Securities [3][12]. Insurance Sector - The report notes a mixed performance in the insurance sector, with property insurance companies showing gains while life insurance companies mostly declined. China Property & Casualty Insurance rose by 5%, while China Taiping fell by 4% [24][25]. - Investors are advised to focus on quality leaders in the insurance sector, with a preference for defensive stocks like China Ping An and China Life Insurance for conservative investors [24][25]. Banking Sector - The banking sector is experiencing a recovery in performance, with Q4 profits improving and net interest margins stabilizing. The report indicates a year-on-year increase in social financing, primarily due to the pre-positioning of government bonds and a rebound in off-balance-sheet financing [28][37]. - Recommended stocks include quality regional banks such as Nanjing Bank and Chengdu Bank, which are expected to perform well due to their strong fundamentals [3][28].

五成公司预告盈利药明康德、三生国健等预盈超10亿 以业绩预告净利润下限统计，已公布2025年业绩预告的274家医药生物上市公司中，137家预计实现盈利，占比五成。 其中，10家公司预告归母净利润超10亿元，包括药明康德、三生国健、吉林敖东等。 新华财经北京2月24日电截至2026年2月12日，根据申万行业分类，A股医药生物行业逾500家上市公司，其中约274家已披露2025年业绩预告。 整体来看，已披露2025年业绩预告的274家医药生物上市公司中，业绩偏正面（包括预增、略增、扭亏及续盈）的企业合计90家。 137家医药生物上市公司2025年实现盈利，占比50%，其中10家归母净利润超10亿元。 图1：A股医药生物行业上市公司2025年业绩预告类型 图3：药明康德2025年度业绩预告 | | 2025年预告利润超过10亿元 | | | --- | --- | --- | | 证券代码 | 证券简称 | 业绩预告类型 | | 603259.SH | 药明康德 | 预增 | | 688336.CH | 三生国健 | 预增 | | 000623.SZ | 吉林敖东 | 预增 | | 688578.SH | 艾力斯 ...

Group 1 - Jilin Aodong's subsidiary Yanbian Pharmaceutical has obtained 10 listings for traditional Chinese medicine formula granules, bringing the total to 535, which is expected to expand the company's business and enhance its core competitiveness [1] - The Ministry of Industry and Information Technology and seven other departments issued the "Implementation Plan for High-Quality Development of Traditional Chinese Medicine Industry (2026-2030)", aiming to cultivate raw material bases and promote industrial upgrades, providing policy benefits for traditional Chinese medicine companies [1] Group 2 - As of February 12, 2026, Jilin Aodong's stock price closed at 18.81 yuan, down 0.48% for the day, with a trading volume of 180 million yuan; net outflow of main funds was 35.58 million yuan, accounting for 19.8% of total trading volume [2] - Over the past five days, the stock price has decreased by 0.69%, and technical indicators show the stock is near the lower Bollinger Band at a support level of 18.21 yuan, indicating overall performance is weaker than the industry average [2]

Group 1 - Jilin Aodong Pharmaceutical Group Co., Ltd. announced that its subsidiary, Yanbian Pharmaceutical Co., Ltd., has obtained 10 "Traditional Chinese Medicine Formula Granule Listing Filing Certificates" [2] - Jilin Aodong is focusing on the development of traditional Chinese medicine formula granules in key regions and medical institutions, primarily targeting grade A hospitals while utilizing three terminals and online platforms for clinical promotion [2] - Yanbian Pharmaceutical has completed its pre-processing workshop, extraction workshop, formulation workshop, and comprehensive R&D building, with multiple production lines passing GMP compliance checks as of January 23, 2025 [2] Group 2 - Jilin Aodong will continue to implement a "pharmaceutical health + financial capital" dual-drive strategy, enhancing the synergy between industry and finance [3] - The company aims to leverage its strong pharmaceutical industry foundation, mature product matrix, and solid market competitive advantages to establish a sustainable development base [3] - Investment returns from financial activities will be reinvested into pharmaceutical R&D, production, and industry chain upgrades, fostering a positive collaboration with the pharmaceutical sector [3]

Core Viewpoint - Jilin Aodong (000623.SZ) announced that its subsidiary, Jilin Aodong Yanbian Pharmaceutical Co., Ltd., has obtained 10 new "Traditional Chinese Medicine Formula Granule Listing Registration Certificates" [1] Group 1: Company Developments - Yanbian Pharmaceutical, as a core enterprise of the company, has significant advantages in the traditional Chinese medicine sector [1] - As of the date of the announcement, the company has accumulated a total of 535 "Traditional Chinese Medicine Formula Granule Listing Registration Certificates" [1] - The acquisition of these certificates is crucial for the company's expansion in the traditional Chinese medicine formula granule business, creating favorable conditions for sustainable development and enhancing the company's core competitiveness [1]

Core Viewpoint - Jilin Aodong (000623.SZ) announced that its subsidiary, Jilin Aodong Yanbian Pharmaceutical Co., Ltd., has obtained 10 new "Traditional Chinese Medicine Formula Granule Listing Filing Certificates" [1] Group 1: Company Developments - Yanbian Pharmaceutical, as a core enterprise of the company, has a competitive advantage in the traditional Chinese medicine sector [1] - As of the date of the announcement, the company has accumulated a total of 535 "Traditional Chinese Medicine Formula Granule Listing Filing Certificates" [1] - The acquisition of these certificates is significant for the company's expansion in the traditional Chinese medicine formula granule business, creating favorable conditions for sustainable development and enhancing core competitiveness [1]

Core Insights - Jilin Aodong (000623.SZ) announced that its subsidiary, Yanbian Pharmaceutical Co., Ltd., has obtained 10 new certificates for the listing of traditional Chinese medicine formula granules, enhancing its competitive edge in the market [1] Group 1 - Yanbian Pharmaceutical has accumulated a total of 535 certificates for traditional Chinese medicine formula granules as of the date of the announcement, which is significant for the company's expansion in this business segment [1] - The acquisition of these certificates is expected to create favorable conditions for the company's sustainable development [1] - This development further strengthens the company's core competitiveness in the traditional Chinese medicine sector [1] Group 2 - The newly obtained formula granules include: 1. Longkui formula granules 2. Tiankuizi formula granules 3. Vinegar Ai Tan formula granules 4. Caoguoren formula granules 5. Mijinyingzi formula granules 6. Cansha formula granules 7. Jiao Baizhu formula granules 8. Dahuang Tan (Medicinal Rhubarb) formula granules 9. Liushenqu formula granules 10. Sweet Leaf Stevia formula granules [2]

Core Viewpoint - Jilin Aodong announced that its subsidiary Yanbian Pharmaceutical has obtained 10 new "Traditional Chinese Medicine Formula Granule Listing Registration Certificates," which include products like Solanum Nigrum Formula Granule and Tianquizi Formula Granule. This development is significant for the company's expansion in the traditional Chinese medicine formula granule business and enhances its core competitiveness. However, product sales are subject to market environment influences, leading to uncertainty, and it is expected that there will be no major impact on performance in the short term [1]. Group 1 - Yanbian Pharmaceutical has received a total of 10 new listing registration certificates for traditional Chinese medicine formula granules [1]. - The total number of such certificates held by Yanbian Pharmaceutical has reached 535 [1]. - The new certificates are expected to significantly aid in the expansion of the company's traditional Chinese medicine formula granule business [1]. Group 2 - The company acknowledges that product sales may be affected by market conditions, introducing an element of uncertainty [1]. - It is anticipated that the recent developments will not have a substantial impact on the company's performance in the short term [1].